Pediatric ESAP 2015 - 2016

The Pediatric Endocrine Self-Assessment Program (Pediatric ESAP™) is a self-study curriculum specifically designed for endocrinologists seeking initial certification or recertification in pediatric endocrinology, program directors interested in a training instrument, and clinicians seeking a self-assessment and a broad review of pediatric endocrinology. Pediatric ESAP consists of Module 1 and Module 2, two 50-question modules with multiple-choice questions in all areas of pediatric endocrinology, diabetes, growth, and metabolism. There is extensive discussion of each correct answer and references. Pediatric ESAP is updated biennially with new questions.

MOC Part 2 Points

Both modules are approved for ABP Part 2 MOC points. Each module is eligible for 20 Part 2 MOC points. Complete both modules to earn 40 MOC points with ABP.


Target Audience

Pediatric ESAP is a self-study curriculum aimed at physicians seeking certification or recertification in pediatric endocrinology, program directors interested in a testing and training instrument, and clinicians seeking a self-assessment and a broad review of pediatric endocrinology.

Learning Objectives

Pediatric ESAP 2015-2016 will allow learners to assess their knowledge of all aspects of pediatric endocrinology.

Upon completion of this educational activity, participants will be able to:

  • Recognize clinical manifestations of pediatric endocrine, growth, and metabolic disorders and select among current options for diagnosis, management, and therapy.
  • Identify risk factors for endocrine and metabolic disorders in pediatric patients and develop strategies for prevention.
  • Evaluate pediatric endocrine and metabolic manifestations of systemic disorders.
  • Use current, evidence-based clinical guidelines and treatment recommendations to guide diagnosis and treatment of pediatric endocrine and metabolic disorders.

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Interpersonal and Communication Skills
Systems-based Practice
Topic Area: 
Adrenal/HPA Axis
Bone and Calciotropic Hormones
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
Endocrine Disruptors
General Endocrinology
Growth Disorders
Hormones and Cancer
Neuroendocrinology and Pituitary
Pediatric Endocrinology
Thyroid/HPT Axis
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Course opens: 
Course expires: 
In-Training / Early Career Member

Rachel I. Gafni, MD
Program Chair (2014-2015)

Bethesda, Maryland

Craig A. Alter, MD
Program Chair (2013-2014)

Professor of Clinical Pediatrics
Children’s Hospital of Philadelphia
Raymond and Ruth Perelman School of Medicine
University of Pennsylvania

Andrew J. Bauer, MD
Director, The Thyroid Center
Children's Hospital of Philadelphia
Associate Professor of Pediatrics
Perelman School of Medicine
University of Pennsylvania

Mark DeBoer, MD, MSc, MCR
Associate Professor of Pediatrics
University of Virginia School of Medicine

Alison M. Boyce, MD
Assistant Professor of Pediatrics
The George Washington University School of Medicine
Children's National Health System

Stephen A. Huang, MD
Director, Thyroid Program
Children’s Hospital Boston

Stephen H. LaFranchi, MD
Professor of Pediatrics
Doernbecher Children’s Hospital
Oregon Health & Science University

Oksana Lekarev, DO
Assistant Professor of Pediatrics
New York-Presbyterian Hospital
Weill Cornell Medical College

Bradley S. Miller, MD, PhD
Associate Professor of Pediatrics
University of Minnesota Masonic Children’s Hospital

Paola A. Palma Sisto, MD
Associate Professor of Pediatrics
Connecticut Children’s Medical Center
University of Connecticut School of Medicine

Lawrence Silverman, MD
Goryeb Children’s Hospital
Atlantic Health System

Constantine A. Stratakis, MD, D(med)Sci
Bethesda, Maryland

Paul S. Thornton, MD
Medical Director, Diabetes and Endocrinology
Director, Congenital Hyperinsulinism Center
Cook Children’s Medical Center

Stuart A. Weinzimer, MD
Associate Professor of Pediatrics
Yale University School of Medicine
Associate Clinical Professor of Nursing
Yale-New Haven Medical Center

Abbie L. Young, MS, CGC, ELS(D)
Medical Editor


As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Pediatric Self-Assessment Committee.


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationships during the content development process for this activity: Bradley S. Miller, MD, PhD, is a consultant and is on the advisory board for Alexion, BioMarin, EndoPharmaceuticals, Genentech, Ispen, Novo Nordisk, Sandoz, and Versartis. He has also received research support from Alexion, Endo Pharmaceuticals, Ipsen, Novo Nordisk, Sandoz, and Versartis. Lawrence Silverman, MD, is a consultant/advisor for Endo Pharmaceuticals, Novo Nordisk, and Abbvie and is a contracted researcher for Prolor and Versartis. Paul S. Thornton, MD, is a consultant/advisor/lecturer for Endo Pharmaceuticals. Stuart A. Weinzimer, MD, is a consultant for Medtronic, Tandem, and Johnson & Johnson. He has received an honorarium from Eli Lilly.

The following committee members reported no relevant financial relationships: Rachel I. Gafni, MD; Craig A. Alter, MD; Andrew J. Bauer, MD; Allison M. Boyce, MD; Mark DeBoer, MD, MSc, MCR; Stephen LaFranchi, MD; Oksana Lekarev, DO; Paola A. Palma Sisto, MD; and Constantine Stratakis, MD, D(Med)Sci.

The medical editor for this program, Abbie L. Young, MS, CGC, ELS(D), reported no relevant financial relationships.

The Endocrine Society staff associated with the development of this program reported no relevant financial relationships.


The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.


The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.


When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.


The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information be disclosed to the learners. Uses of some pharmaceutical agents, medical devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the United States Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” uses be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before prescribing or recommending any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.


This activity is not supported by educational grant(s) or other funds from any commercial supporter.

Available Credit

Accreditation Period

Course opens: 
Course expires: 

Required Hardware/software


To complete this activity, participants must have access to a computer or mobile device with an Internet connection and use a major Web browser, such as Internet Explorer 10+, Firefox 32+, Safari 7+, or Google Chrome 37+. In addition, cookies must be enabled in the browser’s options.